Interim and end-treatment F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride.

To assess the predictive and prognostic aim of interim and end-treatment F-fluorocholine PET/CT (FCH-PET/CT) and Tc-methilen diphosphonate bone scintigraphy (BS) in patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with Radium 223 dichloride (Ra). Prospective and multicentre ChoPET-Rad study including 82 patients with CRPC-BM. Baseline, after 3 (interim) and 6 doses (end-treatment) BS and FCH PET/CT were performed in patients who meet the study criteria.